A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- Biological: Bevacizumab
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- EPS Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT02246049
- Locations
- π―π΅
EPS Corporation, Shinjuku, Tokyo, Japan
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Phase 2
Completed
- Conditions
- Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
- Interventions
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- EPS Corporation
- Target Recruit Count
- 122
- Registration Number
- NCT01836653
- Locations
- π―π΅
EPS Corporation, Shinjuku-ku, Tokyo, Japan
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
Not Applicable
Completed
- Conditions
- Liver MetastasisColorectal Cancer
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- EPS Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT01834014
- Locations
- π―π΅
EPS Corporation, Shinjuku-ku, Tokyo, Japan
Β© Copyright 2025. All Rights Reserved by MedPath